Bacillus coagulans is classified under HS Code 3002.49. This falls under Chapter 30: Pharmaceutical products, specifically Heading 3002 (Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc), under subheading: Toxins, cultures of micro-organisms (excluding yeasts) and similar products; n.e.c. in item 3002.3.
* The data below is specific to the HS code, not the ingredient.
Suppliers
42
Across 14 countries
Shipments
153
from 2022 to 2026
Total weight
3.1M kg
374 TEU · standard 20-foot container units
Last shipment
8 months ago
Last updated at Feb 25, 2026
Growth
↑ 29%
Trade under 3002.49 has increased by 29% over the past 6 months
Trade activity under HS code 3002.49 suggests a supply chain dominated by large fermentation and biological product companies, with 42 suppliers and 153 shipments totaling over 3,100 metric tons between September 2022 and February 2026. The presence of major players like Chr Hansen, Danisco, DSM, and Novozymes indicates that the supply chain is integrated with broader microbial and pharmaceutical production. However, this activity is not confirmed to be ingredient-specific to Bacillus coagulans, as the HS code covers a range of microbial products. The recent growth score of 31.9 suggests moderate expansion, but the data does not isolate Bacillus coagulans volumes, so the signal is indicative rather than definitive.
HS code 3002.49 falls under Chapter 30 (Pharmaceutical products) and covers toxins, cultures of micro-organisms (excluding yeasts), and similar products not elsewhere specified. This classification is broad and includes various microbial cultures, vaccines, and immunological products, meaning it is not exclusive to Bacillus coagulans. The match to Bacillus coagulans was made via a classifier with high confidence, but the code's scope means that shipments may include other microbial products. Therefore, trade volumes and supplier counts should be interpreted as upper-bound estimates for Bacillus coagulans activity, not precise measurements. This limitation is critical for supply chain planning, as actual Bacillus coagulans volumes could be significantly lower.
| Supplier | Shipments | Top customer | Growth | Last shipment | |
|---|---|---|---|---|---|
No suppliers found. | |||||
The supplier landscape appears moderately concentrated, with the top five suppliers (E Nema, Chr Hansen, Novozymes France, Danisco Deutschland, and DSM Food Specialties) accounting for 64 of 153 shipments (about 42%). Germany hosts the largest number of suppliers (13), but many countries have only one or two, indicating a mix of established players and smaller entities. This suggests a diversified but not fragmented market, with a few key players likely controlling significant capacity. For procurement, this implies potential supply security from multiple sources, but also the need to assess the specific capabilities of each supplier for Bacillus coagulans, as the data does not confirm their product focus.
Key supply risks include the lack of ingredient-specific shipment data, which means volumes and supplier counts may include other microbial products. Additionally, several suppliers show recent activity but without explicit manufacturer designation, so their role as direct Bacillus coagulans producers is uncertain. The broad HS code classification also raises regulatory and quality risks, as shipments may not be food-grade. Further diligence should verify each supplier's product portfolio, confirm Bacillus coagulans-specific production, and assess compliance with food-grade standards. The presence of major fermentation companies suggests potential for reliable supply, but the data does not guarantee ingredient-specific availability.
Germany is the most prominent sourcing geography, with 13 suppliers and 75 shipments accounting for over 2.2 million kg, followed by France, Italy, and Canada. The data suggests a strong European supply base, with additional activity in Argentina, Brazil, China, and India. Trade lanes appear to connect these suppliers to customers in the US and other markets, as evidenced by top customers like Danisco USA and Profarm Group US. However, the data does not specify whether these lanes are for Bacillus coagulans specifically or other microbial products under the same HS code. For sourcing strategy, Europe, particularly Germany, is a key region to engage, but verification of ingredient-specific shipments is necessary.
By shipment count
Germany
75 shipments
13 suppliers
2.3M kg total weight
France
21 shipments
4 suppliers
140.9K kg total weight
Italy
12 shipments
5 suppliers
97K kg total weight
Argentina
6 shipments
2 suppliers
84.7K kg total weight
Belgium
6 shipments
2 suppliers
39K kg total weight
Canada
6 shipments
2 suppliers
289.2K kg total weight
China
5 shipments
3 suppliers
79.7K kg total weight
Japan
4 shipments
2 suppliers
10.3K kg total weight
Ireland
4 shipments
1 suppliers
8.1K kg total weight
Brazil
4 shipments
4 suppliers
51.8K kg total weight